Biomedical subjects
Elaine Smith
Publications and source records attributed to Elaine Smith.
Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
PURPOSE: Thalidomide is effective for the treatment of severe cutaneous lupus. Our aim was to study the safety and efficacy of different doses of thalidomide in this condition. METHODS: We studied patients with severe cutaneous lupus that was unresponsive to antimalarials, prednisolone, methotrexate, azathioprine, and cyclosporin A. Starting doses of 100 mg daily (n = 16 patients), 50 mg daily (n = 17), or 50 mg on alternate days (n = 15) were compared. The response to thalidomide was categorized as complete remission, partial remission, or no visible improvement. All patients received a baseline electromyogram (EMG) followed by repeat EMG every 3 to 6 months, or sooner if neuropathic symptoms developed. RESULTS: Forty-eight patients (46 female; mean [+/- SD] age, 44 +/- 12 years; range, 22 to 71 years) with discoid lupus (n = 18), subacute cutaneous lupus (n = 6), or systemic lupus erythematosus with skin involvement (n = 24) were included. The response rate was 81%, including 29 patients (60%) in complete remission and 10 (21%) in partial remission. Nine patients (19%) failed to respond. Thirteen patients (27%) developed peripheral neuropathy, which was EMG-proven in 11, including 4 patients in the 50-mg alternate-day group. Other side effects included drowsiness, constipation or abdominal pain, and amenorrhea. The relapse rate after stopping thalidomide was 67% (26/39). There was no association between a positive response to the drug and either starting doses or cumulative dose. Similarly, no association was found between peripheral neuropathy and the starting or cumulative dose. CONCLUSION: Thalidomide is effective for the treatment of severe cutaneous lupus. There were no clear dose-dependent effects. However, the high incidence of neurotoxicity, even at low doses, suggests that it may be most useful as a remission-inducing drug.
Physician specialty is significantly associated with hormone replacement therapy use.
OBJECTIVE: To compare the characteristics of postmenopausal women seen by gynecologists versus family physicians and to determine factors associated with current hormone replacement therapy (HRT) use. METHODS: We conducted a cross-sectional study of 426 postmenopausal women seen for their annual examination at university clinics. Logistic regression was used to identify predictors of current versus never HRT use. RESULTS: Overall, 60% of women recruited in family practice clinics and 69% in gynecology clinics were current HRT users. Significant, positive, multivariable predictors of HRT use were gynecology versus family practice clinic attendance (odds ratio [OR] 2.6, 95% confidence interval [CI] 1.4, 4.6), surgical menopause (OR 2.3, 95% CI 1.2, 4.6), history of depression (OR 2.3, 95% CI 1.2, 4.7), at least two live births (OR 2.1, 95% CI 1.1, 4.0), and current alcohol use (OR 1.8, 95% CI 1.04, 3.2). Significant, negative, multivariable predictors were increasing age (60-70 years versus less than 60 years, OR 0.4, 95% CI 0.2, 0.8; 70 years or older versus less than 60 years, OR 0.4, 95% CI 0.2, 0.9) and history of breast cancer (OR 0.04, 95% CI 0.01, 0.14). Sociodemographic factors, smoking status, number of self-reported medical conditions, number of prescription medications besides HRT, oral contraceptive use, history of hypertension, and exercise level were tested as covariates and did not enter the model. CONCLUSION: Although current HRT use rates between clinics were similar and higher than national averages, we found that the adjusted odds of current HRT use among women receiving care from gynecologists was 2.6 times that among women receiving care from family physicians. This practice variation may reflect physicians' uncertainty surrounding the preventive value of HRT.
Educational opportunities for experienced staff: do they make a difference?
This study evaluates the impact of educational programs, such as Advanced Burn Life Support (ABLS), on the knowledge base of experienced burn nurses. A convenience sample of six clinical experts within a 21-bed southeastern burn center who had never taken ABLS participated. The quantitative findings display a high level of value and an increase in knowledge base. The results of this study suggest that nurses with high levels of experience will have an increase in knowledge and express value in continuing education curricula. Consequently, this study supports the necessity of educational programs for nurses with significant specialized experience.